Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of MK-0616 in adults with heterozygous familial hypercholesterolemia
MOH_2023-09-28_012857Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing MK-0616 with Placebo (2 arms). Started Sep 2023; status: active, not recruiting.
02
Drugs
enlicitide
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on MOH_2023-09-28_012857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-28_012857.